ArticleAmerican journal of hematology2017
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
Open access · bronzeAbstract readLetter
In one paragraph
Article in American journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 47 citations in OpenAlex.
- Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.Blood advances · 2025Trial
- CAR19/22 T cell therapy in adult refractory Burkitt's lymphoma.Cancer immunology, immunotherapy : CII · 2021Trial
- Tumor-induced dendritic cell deregulation perturbs T cell proliferation and predicts clinical outcome in acute lymphoblastic leukemia.Cell reports. Medicine · 2026Article
- [Chinese expert consensus on the diagnosis and treatment of Burkitt lymphoma (2026)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Two decades of single-institution data reveal rare longterm survivors of relapsed/refractory Burkitt lymphoma.Haematologica · 2026Article
- Novel Molecular Insights and Evolution of Less Toxic Therapeutic Strategies in Burkitt Lymphoma.Cancers · 2025Review
- Rituximab for children with EBV-positive Burkitt lymphoma in East Africa.Blood advances · 2025Observational
- Phosphatidylinositol 3-Kinase Inhibition and Allogeneic Stem Cell Transplantation Can Overcome Chemotherapy Resistance in Refractory Burkitt Lymphoma.Journal of hematology · 2025Article
- Inhibiting the RNA helicase DDX3X in Burkitt lymphoma induces oxydative stress and impedes tumor progression in xenografts.Frontiers in cell and developmental biology · 2025Article
- CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies.Blood neoplasia · 2024Article
- Very late relapse of Burkitt's lymphoma in an EBV-negative patient after 20 years of complete remission.Leukemia research reports · 2024Article
- Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma.Frontiers in immunology · 2024Article
- Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies.Blood and lymphatic cancer : targets and therapy · 2024Review
- Chemotherapy resistant Burkitt lymphoma: Possible novel therapies including CAR-T cell infusion.Clinical case reports · 2023Article
- EBV and Lymphomagenesis.Cancers · 2023Review
- The RNA helicase DDX3 and its role in c-MYC driven germinal center-derived B-cell lymphoma.Frontiers in oncology · 2023Review
- Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report.OncoTargets and therapy · 2023Article
- Blinatumomab in Relapsed/Refractory Burkitt Lymphoma.Cancers · 2022Article
- Urgency and necessity of Epstein-Barr virus prophylactic vaccines.NPJ vaccines · 2022Review
- Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience.Leukemia & lymphoma · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Nicholas J ShortDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-2983-2738
Hagop M KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-1908-3307
Heidi KoDepartment of Internal Medicine, The University of Texas Health Science Center, Houston, Texas, USA.
Joseph D KhouryDepartment of Hematopathology, The University of Texas Health Science Center, Houston, Texas, USA.
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Deborah A ThomasDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Maria KhouriDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jorge E CortesDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
William G WierdaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Srdan VerstovsekDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Zeev EstrovDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Alessandra FerrajoliDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Philip A ThompsonDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sherry PierceDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Susan M O'BrienChao Family Comprehensive Cancer Center, University of California Irvine, Orange, California, USA.
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-4465-6119
The University of Texas MD Anderson Cancer Center · USThe University of Texas Health Science Center at Houston · USUniversity of California, Irvine · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MNCI NIH HHS P30 CA016672
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsAsparaginaseBurkitt LymphomaCyclophosphamideDexamethasoneDisease-Free SurvivalDoxorubicinDrug Resistance, NeoplasmEtoposideFollow-Up StudiesHumansKaplan-Meier EstimateLeukemia, B-CellLymphoma, B-CellAntineoplastic Agents, ImmunologicalAsparaginaseCyclophosphamideDexamethasoneDoxorubicinEtoposideMethotrexatepegaspargasePolyethylene GlycolsPrednisoneRituximabVincristine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.